Skip to main content
. 2019 Apr 19;48(1):1–10. doi: 10.1007/s11239-019-01860-7

Fig. 2.

Fig. 2

Cardiovascular outcomes following de-escalation from ticagrelor to clopidogrel. a Major Adverse Cardiovascular Events (I2 = 0.00%); RE: Random Effects. b Cardiovascular Mortality (I2 = 0.00%); RE: Random Effects. c Myocardial Infarction (I2 = 85.0%); RE: Random Effects